The Role of Bevacizumab in Treatment of Metastatic Cervical Cancer

November 12, 2013
Bradley Monk, MD

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Clinical Pearls

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

  • The recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer
  • Adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%
  • Metastatic cervical cancer was previously though to be resistant to chemotherapy
  • The FDA will be interested in these data, though it remains to be seen if approval will follow